Heart failure affects millions of people worldwide and can significantly impact quality of life. Research into new treatment approaches remains critical to improving outcomes and expanding options for patients living wit...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
From confidence to capital: Positioning biotech for the next growth cycle
How can biotechs position themselves for the next growth cycle? Deepali Suri shares insights on investor readiness, AI, global development strategies and emerging opportunities across biotech.
-
Establishing ctDNA as a validated primary surrogate endpoint
Unlocking faster paths to precision oncology. This article examines the promise of ctDNA as a validated surrogate endpoint and what it could mean for accelerating drug development and expanding patient access to innovative cancer therapies.
-
Chinese drugmakers with big ambitions struggle to recruit staff for global expansion
China's rapid rise as a hub for testing experimental, next-generation medicines is outpacing the industry's ability to build the workforce needed to take those products global.
-
Clinical success for CNS mAbs depends on more than mechanisms of action alone
The success of CNS monoclonal antibodies (mAbs) depends on more than innovative science. Robust clinical operations and safety governance are critical to protecting patients and advancing development. Discover the key operational considerations for neurologic mAbs in the article.
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
Examine how accelerated approvals can unlock earlier market access and why weak biomarker foundations, self-competitive confirmatory trials and payer misalignment remain critical risks.
-
It’s complicated! When APAC global ambition meets regulatory reality
While not all sponsors plan to market treatments beyond the country of origin, many do. Those sponsors with global ambitions must decide which regulatory route offers the most strategic advantages and which market, particularly between the EU and US.
-
June 2026 Medical/Commercial Pulse Check
With the first EU JCAs finalized and CMS extending deadlines for its ambitious Medicaid international-pricing model, ICON and other industry leaders share how they are navigating the friction between global harmonization and local execution including the practical evolution of global pricing floors, the maturing role of AI agents, and the new reality of European access.
-
The Next Wave of Biosimilars: Why Hematology Is a High-Stakes Opportunity
A confluence of patent expiries and rising healthcare costs are accelerating both interest and investment in biosimilars across the world. In this article on Citeline we discuss how this relates to one of the major impacted areas, hematology.
-
When your CRO’s AI platform upgrades, who pays for the change management?
This article examines the operations and cost considerations of ICON’s AI platform evolution, following it’s partnership with Microsoft to scale the Orbis platform across clinical trials.
-
ICON names Microsoft tech partner as Q1 results grow analyst confidence
This article reports on ICON naming Microsoft as a technology partner to scale its Orbis AI platform, while highlighting growing analyst confidence driven by improving performance and demand.
